miR-155 functions downstream of angiotensin II receptor subtype 1 and calcineurin to regulate cardiac hypertrophy

Experimental and Therapeutic Medicine

Volumn 12, Issue 3, 2016, Pages 1556-1562

  Yang, Yong ^a   Zhou, Yong ^a   Cao, Zheng ^a   Tong, Xin Zhu ^a   Xie, Hua Qiang ^a   Luo, Tao ^a   Hua, Xian Ping ^a   Wang, Han Qin ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Angiotensin II receptor type 1; Cardiac hypertrophy; MicroRNA 155

Indexed keywords

APELIN RECEPTOR; ATRIAL NATRIURETIC FACTOR; CALCINEURIN; CALCINEURIN BETA; MICRORNA 155; MYOSIN HEAVY CHAIN BETA; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT4; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CARDIAC MUSCLE CELL; CONTROLLED STUDY; DOWN REGULATION; GENE SEQUENCE; GENETIC TRANSFECTION; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PHASE CONTRAST MICROSCOPY; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPECTROFLUOROMETRY; WESTERN BLOTTING;

EID: 84980340130     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3506     Document Type: Article

References (28)

1. Hill JA and Olson EN: Cardiac plasticity. N Engl J Med 358: 1370-1380, 2008.
2. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW and Young JB; OPTIMIZE-HF Investigators and Coordinators: Predictors of in-hospital mortality in patients hospitalized for heart failure: Insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 52: 347-356, 2008.
3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al: 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128: 1810-1852, 2013.
4. Savoia C, Burger D, Nishigaki N, Montezano A and Touyz RM: Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 13: e11, 2011.
5. Small EM and Olson EN: Pervasive roles of microRNAs in cardiovascular biology. Nature 469: 336-342, 2011.
6. Faraoni I, Antonetti FR, Cardone J and Bonmassar E: miR-155 gene: A typical multifunctional microRNA. Biochim Biophys Acta 1792: 497-505, 2009.
7. Seok HY, Chen J, Kataoka M, Huang ZP, Ding J, Yan J, Hu X and Wang DZ: Loss of microRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res 114: 1585-1595, 2014.
8. Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E, et al: Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 128: 1420-1432, 2013.
9. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, Hatzigeorgiou AG and Antonarakis SE: Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: A mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 81: 405-413, 2007.
10. Marian AJ: Experimental Therapies in Hypertrophic Cardiomyopathy. J Cardiovasc Transl Res 2: 483-492, 2009.
11. Zheng L, Xu CC, Chen WD, Shen WL, Ruan CC, Zhu LM, Zhu DL, Gao PJ, et al: MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts. Biochem Biophys Res Commun 400: 483-488, 2010.
12. Cheng W, Liu T, Jiang F, Liu C, Zhao X, Gao Y, Wang H, Liu Z, et al: microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women. Int J Mol Med 27: 393-399, 2011.
13. Gómez AM, Ruiz-Hurtado G, Benitah JP and Domínguez-Rodríguez A: Ca(2+) fluxes involvement in gene expression during cardiac hypertrophy. Curr Vasc Pharmacol 11: 497-506, 2013.
14. Hogan PG, Chen L, Nardone J and Rao A: Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17: 2205-2232, 2003.
15. Varkonyi-Gasic EI, Wu R, Wood M, Walton EF and Hellens RP: Protocol: A highly sensitive RT-PCR method for detection and quantification of microRNAs. Plant Methods 3: 12, 2007.
16. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
17. Saris JJ, 't Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JM and Jan Danser AH: Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 48: 564-571, 2006.
18. Cavallero S, González GE, Puyó AM, Rosón MI, Pérez S, Morales C, Hertig CM, Gelpi RJ and Fernández BE: Atrial natriuretic peptide behaviour and myocyte hypertrophic profile in combined pressure and volume-induced cardiac hypertrophy. J Hypertens 25: 1940-1950, 2007.
19. Haddad F, Qin AX, Bodell PW, Zhang LY, Guo H, Giger JM and Baldwin KM: Regulation of antisense RNA expression during cardiac MHC gene switching in response to pressure overload. Am J Physiol Heart Circ Physiol 290: H2351-H2361, 2006.
20. Lunde IG, Kvaløy H, Austbø B, Christensen G and Carlson CR: Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT transcription factor isoforms in cardiomyocytes. J Appl Physiol 111: 1278-1289, 2011.
21. Marian AJ: Hypertrophic cardiomyopathy: From genetics to treatment. Eur J Clin Invest 40: 360-369, 2010.
22. Jeppesen PL, Christensen GL, Schneider M, Nossent AY, Jensen HB, Andersen DC, Eskildsen T, Gammeltoft S, Hansen JL and Sheikh SP: Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes. Br J Pharmacol 164: 394-404, 2011.
23. Sayed D, Hong C, Chen IY, Lypowy J and Abdellatif M: MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 100: 416-424, 2007.
24. Kozomara A and Griffiths-Jones S: miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42: D68-73, 2014.
25. Seok HY, Tatsuguchi M, Callis TE, He A, Pu WT and Wang DZ: miR-155 inhibits expression of the MEF2A protein to repress skeletal muscle differentiation. J Biol Chem 286: 35339-35346, 2011.
26. Rinne A and Blatter LA: Activation of NFATc1 is directly mediated by IP3 in adult cardiac myocytes. Am J Physiol Heart Circ Physiol 299: H1701-H1707, 2010.
27. Izumi Y, Kim S, Zhan Y, Namba M, Yasumoto H and Iwao H: Important role of angiotensin II-mediated c-Jun NH(2)-terminal kinase activation in cardiac hypertrophy in hypertensive rats. Hypertension 36: 511-516, 2000.
28. Liu Q, Wilkins BJ, Lee YJ, Ichijo H and Molkentin JD: Direct interaction and reciprocal regulation between ASK1 and calcineurin-NFAT control cardiomyocyte death and growth. Mol Cell Biol 26: 3785-3797, 2006.